Frequently asked questions

  • What is JEMPERLI?

    JEMPERLI is a prescription medicine used to treat adults with:

    • a kind of uterine cancer called endometrial cancer (EC)
      • JEMPERLI may be used in combination with the chemotherapy medicines carboplatin and paclitaxel, and then after that, JEMPERLI may be used alone:
        • when your cancer has spread outside your uterus (advanced) or,
        • your cancer has returned.
      • JEMPERLI may be used alone:
        • when a laboratory test shows that your tumor is mismatch repair deficient (dMMR), and
        • your cancer has returned, or it has spread (advanced EC), and
        • you have received chemotherapy that contains platinum, and it did not work or is no longer working, and
        • your cancer cannot be treated by surgery or radiation.
    • a kind of cancer that is shown by laboratory test to be mismatch repair deficient (dMMR) solid tumor. JEMPERLI may be used alone to treat:
      • cancer that has returned or has spread (advanced cancer) and,
      • has progressed during treatment or after treatment, and you have no satisfactory treatment options.
      • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to confirm the clinical benefit of JEMPERLI for this use.

    It is not known if JEMPERLI is safe and effective in children.

  • How is JEMPERLI given?

    JEMPERLI is given through an intravenous (IV) infusion. It takes approximately 30 minutes.

  • What is immunotherapy?

    Immunotherapy (IH-myoo-noh-THAYR-uh-pee) is a treatment that is designed to work with the body’s immune system to attack cancer cells. JEMPERLI is an immunotherapy that may help your body’s immune system fight cancer.

  • What does dMMR mean?

    dMMR stands for “mismatch repair deficient.” It describes cancers that have an MMR system that is not working properly to correct errors in the genes. dMMR is an important biomarker in endometrial cancer.

  • What is a biomarker?

    A biomarker (BY-oh-MAR-ker) is a molecule found in the tissues or fluids of your body that shows if a condition, process, or disease is normal or abnormal. Endometrial cancer may have a biomarker known as dMMR (mismatch repair deficient). Testing for this biomarker provides important information about your cancer and may help your doctor decide what treatment options, including JEMPERLI, may be right for you.

  • Why is it important to test for biomarkers?

    Testing for biomarkers like dMMR provides information about your cancer and may help your doctor decide what treatment options, including JEMPERLI, may be appropriate for you.

  • How common is endometrial cancer?

    Endometrial cancer is the most common gynecologic malignancy in the US. In 2024, an estimated 61,000 cases will be diagnosed in the US.

  • Is advanced or returned endometrial cancer common?

    About 1 in 4 people with endometrial cancer has cancer that has spread outside the uterus (advanced) or has returned.

  • How many people with endometrial cancer have the dMMR biomarker?

    dMMR is a fairly common biomarker—up to 30% of people with endometrial cancer have it.

  • How has JEMPERLI been studied?

    Researchers have conducted clinical trials to study the effectiveness, risks, and side effects associated with JEMPERLI. Trials are ongoing.

  • How many people participated in the clinical trial of JEMPERLI in combination with carboplatin and paclitaxel?

    There were 494 patients included in the clinical trial that studied the effectiveness of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, compared to carboplatin and paclitaxel alone. They had endometrial cancer that was newly-diagnosed and had spread outside the uterus (advanced) or had returned.

    The clinical trial also studied the risks and side effects of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, in 241 people with newly-diagnosed advanced or returned endometrial cancer.

  • How many people participated in the clinical trial of JEMPERLI alone for advanced or returned dMMR endometrial cancer?

    The clinical trial that studied the effectiveness of JEMPERLI alone included 141 people. They had dMMR endometrial cancer that had returned or spread (advanced); they had also previously received chemotherapy containing platinum that did not work or stopped working.

    The clinical trial also studied the risks and side effects of JEMPERLI alone in 150 people who had advanced or returned dMMR endometrial cancer.

  • How many people participated in the clinical trial of JEMPERLI alone for advanced or returned dMMR solid tumors?

    The clinical trial that studied the effectiveness of JEMPERLI alone for dMMR solid tumors included 209 people. They had dMMR solid tumors that had returned or spread (advanced cancer) and had progressed during or after treatment and had no satisfactory treatment options.

    The clinical trial also studied the risks and side effects of JEMPERLI alone in 267 people who had advanced or returned dMMR solid tumors.

    Studies are ongoing to confirm the clinical benefit of JEMPERLI for this use.

  • What types of dMMR solid tumors were studied in the clinical trial of JEMPERLI alone?

    These people had a variety of dMMR tumor types, including:

    • Endometrial cancer
    • Colorectal cancer
    • Small intestinal cancer
    • Gastric cancers
    • Pancreatic carcinoma
    • Biliary neoplasm
    • Liver cancer
    • Ovarian cancer
    • Adrenal cortical
    • Breast cancer
    • Esophageal cancer
    • Malignant neoplasm of the female genitals
    • Pleural
    • Renal cell carcinoma
    • Unknown origin

    If you have a dMMR solid tumor, talk to your doctor about treatment options.

  • Does GSK offer support and access resources for people being treated with JEMPERLI?

    Yes. Together with GSK Oncology is a free patient resource program for you and your doctor to help with access and financial issues related to JEMPERLI. To learn whether you are eligible, visit Together with GSK Oncology.

    The information provided by Together with GSK Oncology is not a guarantee of coverage.